Pelago Bioscience AB is founded to accelerate the use and value of the CETSA® technology in Drug Discovery and diagnostics. We know that the need for Target Engagement studies is large and increasing and there is no single technology with the same opportunities to fill this need as CETSA®. We will:

- Make more relevant data available to our customers at an earlier stage of the Drug Discovery process
- Enable filtering of compounds based on physiologically relevant data to facilitate better decisions in Drug Discovery programs
- Provide our customers with CETSA® based Target Engagement data in vitro and in vivo
- Improve translation from laboratory to patient by using a single technology - CETSA®
- Facilitate development of novel medicine in clinical trials using CETSA®
- Develop diagnostic kits, companion diagnostics and tools for monitoring Target Engagement during patient treatment using CETSA®

Pelago Bioscience AB will by these accomplishments add value to Drug Discovery programs allowing for faster and better development of new and improved drugs. By developing the CETSA® technology for general clinical use as a diagnostic and treatment monitoring tool we aspire to improve the lives and health of patients.

Biotechnology

Life Sciences

Pharmaceutical

Therapeutics

Pelago Bioscience AB

Pelago Bioscience AB's headquarters in Solna, Sweden

Michael Dabrowski

Maria Hjortsmark

Johan Karlsson

Kia Pedersen

Daniel Martinez Molina

Description

People (11)

Michael Dabrowski

Daniel Martinez Molina

Ulla Sundberg

Victoria Brehmer

Kia Pedersen

Indrachapa Balasooriya

Alla Ivaskova

Bora Baskaner

Johan Karlsson

Alexey Chernobrovkin

Phathu Muthelo

Jobs